Eli Lilly Shares Surge on Dual Catalysts: New Drug Approval and Major Acquisition

Eli Lilly & Company’s stock posted significant gains, outperforming the broader pharmaceutical sector, following two major announcements. The company secured U.S. regulatory approval for a new weight-loss medication and simultaneously revealed a multi-billion dollar acquisition aimed at the sleep disorder market.

Strategic Acquisition Targets Lucrative Sleep Market

In a move to diversify its pipeline, Eli Lilly has agreed to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion. An upfront cash payment of $6.3 billion, or $38 per share, represents a 37% premium to Centessa’s closing price on March 30. The transaction includes potential contingent value rights of up to $9 per share, tied to the achievement of specific regulatory milestones.

The centerpiece of the acquisition is the experimental drug cleminorexton (ORX750), an orexin receptor 2 agonist currently in Phase 2 trials for treating narcolepsy and idiopathic hypersomnia. Market analysts estimate the potential orexin-targeted therapy market at $15 to $20 billion, with future applications possibly extending to conditions like ADHD and Alzheimer’s disease. Financial experts view the purchase as a strategic reinvestment of the substantial cash flows generated by Lilly’s established GLP-1 franchise. The acquisition is scheduled for completion in the third quarter of 2026.

Should investors sell immediately? Or is it worth buying Eli Lilly?

Foundayo Approval Expands Weight-Loss Portfolio with Patient-Friendly Option

The U.S. Food and Drug Administration (FDA) has cleared Eli Lilly’s oral weight-management drug, Foundayo (orforglipron), for use. The medication will be available through the LillyDirect digital platform starting April 6. Pricing is set at $25 per month for patients with private insurance, while out-of-pocket costs for self-pay patients will range from $149 to $349, depending on dosage. Furthermore, coverage under Medicare Part D is expected to begin on July 1, 2026.

Foundayo distinguishes itself from existing GLP-1 therapies as a non-peptidic small molecule, meaning it does not require specific food or fluid restrictions upon administration. This offers a notable convenience advantage. In the pivotal ATTAIN-1 Phase 3 trial, participants on the highest dose achieved an average weight reduction of 12.4%, compared to 0.9% for those in the placebo group. Market researchers project Foundayo could generate nearly $15 billion in annual sales by 2030.

Market Outlook and Price Targets

Following these developments, the consensus price target among analysts covering Eli Lilly stands at $1,201 per share. Compared to a recent trading price of approximately $824, this suggests considerable upside potential, contingent on the successful execution of both the new drug launch and the integration of the acquired assets.